Recordati SpA Az nom Post raggruppamento RCDTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $51.98
- Day Range
- $51.60–51.60
- 52-Week Range
- $40.93–51.60
- Bid/Ask
- $51.87 / $56.87
- Market Cap
- $10.65 Bil
- Volume/Avg
- 1,440 / 1,159
Key Statistics
- Price/Earnings (Normalized)
- 18.91
- Price/Sales
- 4.79
- Dividend Yield (Trailing)
- 2.46%
- Dividend Yield (Forward)
- 2.65%
- Total Yield
- 2.46%
Company Profile
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 4,300
- Website
- https://www.recordati.com
Comparables
Valuation
|
Metric
|
RCDTF
|
PHIL
|
CRNX
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.91 | 325.08 | — |
Price/Book Value | 5.70 | 8.11 | 5.59 |
Price/Sales | 4.79 | 31.58 | 639.90 |
Price/Cash Flow | 16.73 | — | — |
Price/Earnings
RCDTF
PHIL
CRNX
Financial Strength
|
Metric
|
RCDTF
|
PHIL
|
CRNX
|
|---|---|---|---|
Quick Ratio | 0.82 | 6.82 | 12.92 |
Current Ratio | 1.28 | 7.02 | 13.07 |
Interest Coverage | 8.43 | −11.02 | — |
Quick Ratio
RCDTF
PHIL
CRNX
Profitability
|
Metric
|
RCDTF
|
PHIL
|
CRNX
|
|---|---|---|---|
Return on Assets (Normalized) | 12.84% | −0.47% | −38.81% |
Return on Equity (Normalized) | 32.17% | −0.91% | −44.79% |
Return on Invested Capital (Normalized) | 17.08% | −0.46% | −45.62% |
Return on Assets
RCDTF
PHIL
CRNX
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Pjvwsssk | Wrqlp | $695.3 Bil | |
JNJ
| Johnson & Johnson | Dfxyddvnf | Pfb | $359.3 Bil | |
MRK
| Merck & Co Inc | Dlvftgzq | Nqqf | $321.5 Bil | |
ABBV
| AbbVie Inc | Tvzfvvr | Kyl | $297.3 Bil | |
AZN
| AstraZeneca PLC ADR | Gtcjjndl | Xcnm | $215.8 Bil | |
RHHBY
| Roche Holding AG ADR | Sqgzydckhp | Wzlh | $203.2 Bil | |
NVS
| Novartis AG ADR | Zddwmzn | Nkqv | $196.0 Bil | |
PFE
| Pfizer Inc | Lxmcgkgf | Wgkd | $148.7 Bil | |
AMGN
| Amgen Inc | Dbqvfvcnhq | Ttxc | $145.8 Bil | |
SNY
| Sanofi SA ADR | Hpcvlzx | Kqbq | $117.3 Bil |